Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab added to carboplatin + paclitaxel as first-line treatment for ovarian, fallopian tube, or primary peritoneal carcinoma
NL-OMON39830Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jan 2011
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Avastin + carboplatin + paclitaxel with Carboplatin + paclitaxel control (2 arms). Primary endpoint: Primary endpoint(s). Started Jan 2011; status: recruiting.
02
Drugs
bevacizumabcarboplatinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON39830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39830.